Physician profile
Emily Schaffer
NPI 1215414446
$5,087.92
in general payments reported to CMS, 2019-2025
26 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,184 · 2022: $1,101 · 2023: $1,214 · 2024: $485 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,802.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,802.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,636.69 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $794.65 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $423.84 | 2022-2024 | Caplyta |
| Sunovion Pharmaceuticals INC. | $383.27 | 2021-2022 | |
| Lundbeck LLC | $321.60 | 2021-2024 | Rexulti, Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $248.72 | 2021-2025 | Abilify Maintena, Rexulti |
| Supernus Pharmaceuticals, INC. | $188.73 | 2022-2024 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $149.81 | 2021-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $108.33 | 2022-2024 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $101.95 | 2021-2024 | Austedo Xr |
| Axsome Therapeutics, INC. | $95.76 | 2023-2024 | Auvelity |
| Corium, LLC | $95.75 | 2022-2023 | Azstarys |
| Bausch Health US, LLC | $84.29 | 2021-2022 | |
| Alkermes, INC. | $76.36 | 2022-2023 | Aristada, Lybalvi |
| Neos Therapeutics, LP | $69.74 | 2021-2023 | Adzenys Xr-Odt |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $65.93 | 2023 | Dyanavel Xr |
| Adlon Therapeutics L.P. | $39.94 | 2021 | |
| Eisai INC. | $37.38 | 2021 | |
| Idorsia Pharmaceuticals US INC | $27.75 | 2023-2024 | Quviviq |
| Almatica Pharma LLC | $25.97 | 2024 | Loreev Xr |
| Tempus Ai, INC | $23.02 | 2024 | |
| Harmony Biosciences LLC | $21.15 | 2022 | |
| Boston Scientific Corporation | $19.75 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.01 | 2024 | Cobenfy |
| Noven Therapeutics, LLC | $16.70 | 2023 | Secuado |
| Jazz Pharmaceuticals INC. | $12.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Schaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.